Effectiveness of low doses (50 and 100 μg b.i.d.) of Beclomethasone dipropionate delivered as a CFC-free extrafine aerosol in adults with mild to moderate asthma

Journal of Asthma

Volumn 37, Issue 5, 2000, Pages 389-398

  Hampel, F ^a   Lisberg, E ^a   Guerin, J C ^a   Benezet, O ^a   Berger, W ^a   Blaive, B ^a   Blanchon, F ^a   Bosser Sanquer, F ^a   Chervinksy, P ^a   Dockhorn, R ^a   Gross, G ^a   Grossman, J ^a   Jacobson, K ^a   Kaiser, H ^a   Lawrence, M ^a   Muir, J F ^a   Nathan, R ^a   Ode, P ^a   Ostrom, N ^a   Pearlman, D ^a   Philippe, J E ^a   Poudenx, M ^a   Prenner, B ^a   Prud'homme, A ^a   Ratner, P ^a   Ravel, T ^a   Schenkel, E ^a   Segall, N ^a   Stricker, W ^a   Taytard, A ^a   Vandewalker, M L ^a   Virant, F ^a   Wanderer, A ^a   more..

^a NONE   (United States)

Author keywords

Asthma; Beclomethasone dipropionate; Hydrofluoroalkane formulation

Indexed keywords

BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; NORFLURANE; PLACEBO; PROPELLANT; STEROID;

ADULT; AEROSOL; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; MULTICENTER STUDY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 0033798646     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.3109/02770900009055464     Document Type: Article

References (20)

1. Airway remodelling takes place in asthma - What are the clinical implications?
2. Early use of inhaled steroids in children with asthma
3. Why the environment matters
4. Improved lung deposition and decreased oro-pharyngeal deposition with a new CFC-free beclomethasone metered dose inhaler
5. Twentyeight-day double blind safety study of an HFA-134a inhalation aerosol system in healthy subjects
6. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler
7. Improved performance characteristics of CFC-free aerosol MDIs
8. Improved airway targeting with CFC-free HFA-BDP MDI compared to CFC
9. 1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group
10. Clinical pharmacology of corticosteroids in bronchial asthma
11. Equivalent asthma symptom control of 1500 MCG beclomethasone dipropionate (BDP) achieved with 800 MCG BDP from fine aerosol solution
12. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma
13. Efficacy response of inhaled beclomethasone in asthma is proportional to dose and is improved by formulation with a new propellant
14. Improved asthma symptom control with 100 μg/day HFA-BDP but not with 100 μg/day CFC-BDP
15. Use of inhaled corticosteroids in patients with mild asthma
16. Fluticasone propionate aerosol: Efficacy in patients with mild to moderate asthma
17. Effect of low dose beclomethasone dipropionate on asthma control and airway inflammation